Here is one I just dug up. Kind of opposite what Texas Univ. states. This study was done in Italy and the UK.
A new study published in the most recent issue of the journal Phytomedicine, and published online by the National Institute of Health, has found that cannabis-based medicines may provide a cure for colon cancer.
For the study, researchers “investigated the effect of a standardized Cannabis sativa extract with high content of cannabidiol (CBD), here named CBD BDS, i.e. CBD botanical drug substance, on colorectal cancer cell proliferation and in experimental models of colon cancer in vivo.”
While conducting the study, it was found that; “CBD reduced cell proliferation in tumoral, but not in healthy, cells. In vivo, CBD reduced AOM-induced preneoplastic lesions and polyps as well as tumour growth in the xenograft model of colon cancer.”
Researchers conclude that “CBD attenuates colon carcinogenesis and inhibits colorectal cancer cell proliferation via CB1 and CB2 receptor activation. The results may have some clinical relevance for the use of Cannabis-based medicines in cancer patients.”
The study, which was conducted by researchers at the University of Naples Federico II in Italy and the University of Aberdeen in the United Kingdom, can be found by clicking here.
Source: TheJointBlog.Com
Phytomedicine. 2014 Apr 15;21(5):631-9. doi: 10.1016/j.phymed.2013.11.006. Epub 2013 Dec 25.
Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol.
Romano B1, Borrelli F2, Pagano E2, Cascio MG3, Pertwee RG3, Izzo AA4.
Author information
Abstract
PURPOSE:
Colon cancer is a major public health problem. Cannabis-based medicines are useful adjunctive treatments in cancer patients. Here, we have investigated the effect of a standardized Cannabis sativa extract with high content of cannabidiol (CBD), here named CBD BDS, i.e. CBD botanical drug substance, on colorectal cancer cell proliferation and in experimental models of colon cancer in vivo.
METHODS:
Proliferation was evaluated in colorectal carcinoma (DLD-1 and HCT116) as well as in healthy colonic cells using the MTT assay. CBD BDS binding was evaluated by its ability to displace [(3)H]CP55940 from human cannabinoid CB1 and CB2 receptors. In vivo, the effect of CBD BDS was examined on the preneoplastic lesions (aberrant crypt foci), polyps and tumours induced by the carcinogenic agent azoxymethane (AOM) as well as in a xenograft model of colon cancer in mice.
RESULTS:
CBD BDS and CBD reduced cell proliferation in tumoral, but not in healthy, cells. The effect of CBD BDS was counteracted by selective CB1 and CB2 receptor antagonists. Pure CBD reduced cell proliferation in a CB1-sensitive antagonist manner only. In binding assays, CBD BDS showed greater affinity than pure CBD for both CB1 and CB2 receptors, with pure CBD having very little affinity. In vivo, CBD BDS reduced AOM-induced preneoplastic lesions and polyps as well as tumour growth in the xenograft model of colon cancer.
CONCLUSIONS:
CBD BDS attenuates colon carcinogenesis and inhibits colorectal cancer cell proliferation via CB1 and CB2 receptor activation. The results may have some clinical relevance for the use of Cannabis-based medicines in cancer patients.
Copyright © 2013 Elsevier GmbH. All rights reserved.
KEYWORDS:
?(9)-Tetrahydrocannabinol; Cancer cell growth; Cannabidiol; Cannabinoid receptors; Chemoprevention; Colorectal cancer
PMID: 24373545 [PubMed - in process]